BRCR Medical Center | Plantation, FL

Research site

(Unclaimed)

Location

8200 W Sunrise Boulevard Suite D1 -D2, Plantation, Florida, United States of America

Site insights

Top conditions

Top treatments

Docetaxel

Cyclophosphamide

Dexamethasone

Platinum

Ontamalimab

Isatuximab

Lenalidomide

Paclitaxel

Pomalidomide

Atezolizumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

29 of 47 total trials

A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation

A Phase 1 dose escalation study in patients with advanced solid tumors harboring KRAS G12C mutation to determine the maximum tolerated dose and recom...

Enrolling

Solid Tumor

Cancer of Pancreas

Drug: HBI-2438

A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations

A Phase 1 dose escalation study in patients with advanced solid tumors harboring KRAS or EGFR mutations to determine the maximum tolerated dose and r...

Enrolling

Solid Tumor

Cancer of Colon

Drug: HBI-2376

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced sol...

Enrolling

HER2-positive Advanced Solid Tumor

Drug: Itraconazole

Drug: Ritonavir

A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera (VERIFY)

The study is designed to evaluate the safety and efficacy of rusfertide in subjects with polycythemia vera (PV) in maintaining hematocrit control and...

Active, not recruiting

Polycythemia Vera

Drug: Placebo

Drug: Rusfertide

A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. (InMIND)

This is a Phase 3 double-blind, placebo-controlled, randomized study designed to investigate whether tafasitamab and lenalidomide as an add-on to rit...

Active, not recruiting

Marginal Zone Lymphoma

Follicular Lymphoma

Drug: tafasitamab

Drug: placebo

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

The purpose of the study is to evaluate the overall survival of participants treated with imetelstat compared to best available therapy with intermed...

Enrolling

Myelofibrosis

Drug: Imetelstat

Drug: Best Available Therapy (BAT)

A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease (CULTIVATE)

This is a Phase 2/3 study that comprises 5 substudies designed to evaluate the efficacy, safety, and tolerability of oral etrasimod as therapy in adu...

Enrolling

Crohn's Disease

Drug: Placebo

Drug: Etrasimod

A Study of DB-1311 in Advanced/Metastatic Solid Tumors

This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311 in subjects with advanced solid tumo...

Enrolling

Advanced Solid Tumors

Drug: DB-1311

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

The purpose of this study is to evaluate two study medicines (encorafenib plus cetuximab) taken alone or together with standard chemotherapy for the...

Active, not recruiting

Neoplasms

Drug: Cetuximab

Drug: Oxaliplatin

A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. (SYMPHONY-1)

The participants of this study would have relapsed/refractory follicular lymphoma.Follicular lymphoma is a type of blood cancer. It is referred to as...

Enrolling

Relapsed/Refractory Follicular Lymphoma

Follicular Lymphoma

Combination Product: Rituximab

Drug: Placebo oral tablet

A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (BRUIN CLL-322)

The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm...

Enrolling

Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia

Drug: Venetoclax

Drug: Rituximab

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions (INDEPENDENCE)

The purpose of this Phase 3 study is to evaluate the efficacy and safety of Luspatercept compared with placebo in subjects with myeloproliferative ne...

Active, not recruiting

Anemia

Myelofibrosis

Other: Placebo

Drug: ACE-536

Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies

The purpose of this study is to evaluate the antitumor effects of sotorasib and RMC-4630 in subjects with KRASG12C mutant NSCLC

Active, not recruiting

Non-Small Cell Lung Cancer

Drug: RMC-4630

Drug: Sotorasib

DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (VITALIZE)

This is a Phase 2b, randomized, open label study to assess the safety and efficacy of DPX-Survivac and pembrolizumab, with and without low-dose cyclo...

Enrolling

Refractory Diffuse Large B-cell Lymphoma

Relapsed Diffuse Large B-cell Lymphoma

Drug: DPX-Survivac

Drug: Pembrolizumab

Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)

The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of TTFields, using the NovoTTF-200T device, c...

Active, not recruiting

Nonsmall Cell Lung Cancer

NSCLC

Drug: Immune checkpoint inhibitors or docetaxel

Device: NovoTTF-200T

Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)

Brief Summary:The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of Tumor Treating Fields (TTFie...

Active, not recruiting

Pancreas Adenocarcinoma

Drug: nab paclitaxel

Drug: Gemcitabine

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer (VIRO-25)

This Phase 2, open-label, randomized study in non-small-cell lung cancer (NSCLC) is designed to evaluate the efficacy and safety of an intravenously...

Enrolling

Metastatic Non-squamous Non Small Cell Lung Cancer

Non-small Cell Lung Cancer

Drug: Docetaxel

Drug: Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab

ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

The goal of this clinical trial is to test ELVN-002 in people with cancers that have an abnormal HER2 gene. The main question the trial aims to answe...

Enrolling

HER2 Mutant Non-small Cell Lung Cancer

HER2 Amplification

Drug: ELVN-002

Drug: Trastuzumab emtansine

ELVN-002 with Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

The purpose of this study is to determine the safety, tolerability, and recommended dose of ELVN-002 in combination with trastuzumab in participants...

Enrolling

HER2 Positive Solid Tumors

HER2-positive Gastric Cancer

Drug: paclitaxel

Drug: Leucovorin

Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors

A Phase 1/2a Open-Label Dose Escalation and Dose Expansion Study of T3011 when Administered Intravenously as a Single Agent and in Combination with O...

Active, not recruiting

Endometrial Cancer

Solid Tumor

Biological: T3011